#NANETS2025
The NANETS Symposium program delivers a robust, clinically focused agenda designed to elevate your understanding of NET disease from multiple disciplines: https://nanets.net/program/schedule

#NANETS2025 #NETSymposium
August 27, 2025 at 8:25 PM
177Lu-edotreotide can improve PFS when compared to everolimus in patients with grade 1-2 GEP-NETs, according to a study presented at #NANETS2025 by Dr Jaume Capdevila of @vhio.bsky.social. www.cancertherapyadvisor.com/reports/177l...
October 27, 2025 at 1:57 PM
Join us at the NANETS Annual Symposium! 🦓 This three-day event remains the leading annual educational conference focused exclusively on NET disease.

🔗 Register now: https://nanets.net/symposium

#NANETS2025 #NETCare #MedicalEducation #NETSymposium
August 13, 2025 at 7:46 PM
Congrats to Dr. Suzann Duan (UC Irvine), recipient of NANETS’ 2025 BTSI Award! Her grant, supported by Neuroendocrine Tumor Research Foundation (NETRF), will advance research on menin-MLL inhibitors for GEP-NETs. She'll be recognized at #NANETS2025 in Austin this October. 🎉
August 26, 2025 at 7:28 PM
For this year's symposium, we are doing away with concurrent sessions. That means every attendee has access to the same dynamic programming, all in one room, bringing experts and attendees together.

🦓 Learn more: https://nanets.net/program/schedule

#NANETS2025 #MedicalEducation #NETSymposium
September 16, 2025 at 6:11 PM
Hotel rooms are filling fast! Book your accommodations at the JW Marriott Austin before the room block closes on September 29. Walk directly from your room to the heart of the event.

Book now: https://nanets.net/travel/hotel-accommodations

#NANETS2025 #NETCare #MedicalEducation #NETSymposium
September 26, 2025 at 6:24 PM
Register now for the Annual Symposium! Standard registration rates are in effect through September 21. Members receive discounted pricing, sign in to access your rate and reserve your spot.

🔗 Register now: https://nanets.net/program/register-now

#NANETS2025 #NETCare #NETSymposium
September 19, 2025 at 6:20 PM
PRRT retreatment is well tolerated and confers a survival benefit in patients with well-differentiated, metastatic NETs, according to a study presented at #NANETS2025. www.cancertherapyadvisor.com/reports/prrt...
October 27, 2025 at 1:48 PM